Objective:To reach the estimated 84.1 million U.S. adults with prediabetes, lower-cost alternatives to the National Diabetes Prevention Program (NDPP) are needed, which is estimated to cost $500 per person. In a previous randomized controlled trial, we demonstrated efficacy of a 12-month text message support program (SMS4PreDM) in individuals with prediabetes. We now explore effectiveness in a pragmatic study in a healthcare system, in addition to calculating per-person costs of SMS4PreDM. Research Design and Methods:English- and Spanish-speaking patients with diabetes risks (e.g., A1C 5.7-6.4) were referred by their healthcare providers and offered NDPP classes, SMS4PreDM, or both. This analysis focused on comparing weight outcomes among SMS4PreDM-only participants to a usual care control group of patients with diabetes risks who were not referred. As a pragmatic study, weights for both groups were collected from electronic health records at baseline and 12 months. Rates of achieving ≥3% weight loss were compared using logistic regression, including a sub-analysis by language. Results:Among 183 SMS4PreDM-only participants, 51.4% (N=94) had documented pre- and post-intervention weights and 30.9% (N=29) achieved ≥3% weight loss, compared with 23.4% of 1,871 control patients (p=0.10). English-speakers receiving SMS4PreDM trended toward ≥3% weight loss at a higher rate than English-speaking controls (36.5% vs. 25.6%, p=.07). There was no significant difference among Spanish-speakers. In an intention-to-treat analysis that assumed no weight loss among participants with missing data, there was no significant difference in achieving ≥3% weight loss as compared to controls (20.8% vs. 20.2%, p=.49). Costs of SMS4PreDM were$100.92 per capita.

Conclusions:SMS4PreDM trends toward greater achievement of ≥3% weight loss compared to usual care and at a lower cost than the NDPP. However, results may not be sufficiently robust or generalizable to support long-term implementation.

Disclosure

H. Fischer: None. S. Raghunath: None. J. Durfee: None. N. Ritchie: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.